| HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer | Trastuzumab | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 2026-11-17 |
| HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers | Pertuzumab, Trastuzumab | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2026-11-16 |
| A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients | Trastuzumab, Trastuzumab deruxtecan | Phase 2 | Not yet recruiting | Centre Leon Berard | 2026-11-13 |
| Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC | Trastuzumab | Phase 2 | Not yet recruiting | Harbin Medical University | 2026-11-13 |
| Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 Study | Pertuzumab, Trastuzumab | Phase 1 | Not yet recruiting | The Netherlands Cancer Institute | 2026-11-10 |
| Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation | Trastuzumab | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2026-11-09 |
| 3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy | Trastuzumab | — | Recruiting | Region Skane | 2026-11-04 |
| Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ | Trastuzumab | Phase 2 | Not yet recruiting | Fudan University | 2026-11-03 |
| Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN) | Trastuzumab deruxtecan | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria Careggi | 2026-10-29 |
| A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) | Zanidatamab | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 2026-10-28 |
| Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer | Pyrotinib | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2026-10-23 |
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer | Disitamab vedotin | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 2026-10-16 |
| Comparative Study of QL1209 and Perjeta® in Healthy Male Participants | Pertuzumab | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 2026-10-06 |
| Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer | Pertuzumab | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 2026-10-05 |
| Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | Pertuzumab, Trastuzumab emtansine | — | Recruiting | Fundación Santa Fe de Bogota | 2026-10-02 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response | Pertuzumab | Phase 2 | Not yet recruiting | Fudan University | 2026-10-02 |
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer | Disitamab vedotin | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2026-10-01 |
| HER2-positive Breast Cancer Without Intravenous Neoadjuvant Therapy | Pertuzumab | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 2026-09-30 |
| Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors | Zanidatamab | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 2026-09-25 |
| A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd | Pyrotinib, Trastuzumab deruxtecan | Phase 2 | Not yet recruiting | Fujian Medical University | 2026-09-23 |
| Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan | Trastuzumab deruxtecan | Phase 3 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 2026-09-18 |
| Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer | Trastuzumab deruxtecan, Trastuzumab emtansine | Phase 2 | Not yet recruiting | Fudan University | 2026-09-17 |
| Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab | Pertuzumab, Pyrotinib | — | Active, not recruiting | Beijing 302 Hospital | 2026-09-09 |
| Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC | Pyrotinib | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 2026-09-01 |
| SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer | Pyrotinib | Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 2026-08-26 |
| A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure | Disitamab vedotin | Phase 1 | Not yet recruiting | Xiangya Hospital of Central South University | 2026-08-25 |
| Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer | Trastuzumab deruxtecan | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 2026-08-25 |
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA | Zanidatamab | — | Not yet recruiting | Jazz Pharmaceuticals | 2026-08-24 |
| A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer | Trastuzumab deruxtecan | Not applicable | Not yet recruiting | Shuangyue Liu | 2026-08-24 |
| Tucatinib Continuation Study | Tucatinib | Phase 4 | Not yet recruiting | Pfizer | 2026-08-17 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer | Pyrotinib | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 2026-08-14 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer | Disitamab vedotin | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 2026-08-10 |
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer | Zanidatamab | Phase 3 | Not yet recruiting | UNICANCER | 2026-08-04 |
| A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma | Disitamab vedotin | Phase 2 | Not yet recruiting | West China Hospital | 2026-08-03 |
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer | Neratinib | Phase 2 | Not yet recruiting | University of California, San Diego | 2026-07-27 |
| SMP-656 for HER2-Positive Advanced Breast Cancer | Trastuzumab deruxtecan | Phase 2 | Recruiting | Chengdu SciMount Pharmatech Co., Ltd. | 2026-07-24 |
| Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 ) | Disitamab vedotin | Phase 2 | Not yet recruiting | Peking University First Hospital | 2026-07-22 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer | Disitamab vedotin | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2026-07-21 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | Pyrotinib | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 2026-07-16 |
| Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC | Disitamab vedotin | Phase 3 | Recruiting | Zhiquan Hu | 2026-07-09 |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study | Zanidatamab | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 2026-07-06 |
| A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | Trastuzumab emtansine | Phase 3 | Recruiting | GeneQuantum Healthcare (Suzhou) Co., Ltd. | 2026-06-29 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer | Afatinib, Pyrotinib | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 2026-06-17 |
| An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Zanidatamab | Phase 2 | Not yet recruiting | Haihua Yuan | 2026-06-08 |
| Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids | Trastuzumab emtansine | — | Recruiting | Guangzhou Institute of Respiratory Disease | 2026-05-28 |
| A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer | KN-026 | Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-05-19 |
| GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting | Tucatinib, Trastuzumab emtansine | — | Recruiting | Fondazione Oncotech | 2026-05-13 |
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | Trastuzumab emtansine | Phase 3 | Recruiting | SWOG Cancer Research Network | 2026-05-11 |
| A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant Therapy | Trastuzumab emtansine | — | Not yet recruiting | Hebei Medical University Fourth Hospital | 2026-04-20 |
| Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer | Tucatinib, Zanidatamab | Phase 1 / Phase 2 | Not yet recruiting | MedSIR | 2026-03-27 |
| Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer | Zanidatamab | Phase 1 / Phase 2 | Not yet recruiting | Universitaire Ziekenhuizen KU Leuven | 2026-03-17 |
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | KN-026 | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 2026-03-02 |
| De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer | Trastuzumab emtansine | Phase 2 | Active, not recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 2026-02-19 |
| RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive | Tucatinib | Phase 2 / Phase 3 | Recruiting | Hoffmann-La Roche | 2026-02-17 |
| Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer | Neratinib | Phase 2 | Not yet recruiting | Xijing Hospital | 2026-01-12 |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | KN-026 | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 2026-01-12 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | Tucatinib | Early phase 1 | Recruiting | M.D. Anderson Cancer Center | 2026-01-06 |
| Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer | Tucatinib | Phase 2 | Recruiting | Institut Curie | 2025-09-25 |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Afatinib | Phase 3 | Recruiting | ArriVent BioPharma, Inc. | 2025-09-22 |
| RT for Adenocarcinoma/Adenosquamous Carcinoma | Neratinib | Phase 1 / Phase 2 | Active, not recruiting | Peking Union Medical College Hospital | 2025-09-04 |
| T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis | Neratinib, Lapatinib | Phase 2 | Recruiting | Fudan University | 2025-09-03 |
| Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study | Neratinib | — | Not yet recruiting | Hebei Medical University Fourth Hospital | 2025-06-13 |
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma | Afatinib | Phase 1 / Phase 2 | Active, not recruiting | West China Hospital | 2025-06-08 |
| JSKN003 Combined Treatment of HER2-positive Gastric Cancer | KN-026 | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 2025-05-31 |
| Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib | Tucatinib | Not applicable | Recruiting | Duke University | 2025-05-21 |
| Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients | Neratinib | Not applicable | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2025-03-24 |
| A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis. | Tucatinib | — | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-21 |
| Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy | Margetuximab, Neratinib, Lapatinib | Early phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 2025-02-14 |
| Using Tumor Models to Determine Treatments | Neratinib | Phase 2 | Recruiting | University Health Network, Toronto | 2025-02-06 |
| FHND9041 Versus Afatinib for Non-small Cell Lung Cancer | Afatinib | Phase 3 | Enrolling by invitation | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 2025-01-06 |
| A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma | Afatinib | Phase 1 / Phase 2 | Recruiting | West China Hospital | 2024-12-31 |
| A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | KN-026 | Phase 3 | Active, not recruiting | Shanghai JMT-Bio Inc. | 2024-12-24 |
| Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC | Afatinib | Phase 2 | Recruiting | Shandong Public Health Clinical Center | 2024-11-29 |
| Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Afatinib | Phase 1 / Phase 2 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2024-10-18 |
| EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study | Afatinib | Phase 3 | Recruiting | Region Skane | 2024-07-03 |
| A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | HEMAY-022, Lapatinib | Phase 3 | Recruiting | Tianjin Hemay Pharmaceutical Co., Ltd | 2024-03-15 |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | Anvatabart opadotin | Phase 2 | Recruiting | Laura Huppert, MD, BA | 2024-01-25 |
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC | KN-026 | Phase 2 | Recruiting | Peking University | 2023-09-05 |
| KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | KN-026 | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 2023-08-14 |
| Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | KN-026 | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 2023-05-01 |
| Antineoplastic Drugs in Elderly Patients | Lapatinib | — | Recruiting | Shandong University | 2022-07-20 |
| MARGetuximab Or Trastuzumab (MARGOT) | Margetuximab | Phase 2 | Active, not recruiting | Dana-Farber Cancer Institute | 2020-06-11 |
| Implantable Microdevice In Primary Brain Tumors | Lapatinib | Early phase 1 | Recruiting | Oliver Jonas | 2019-10-23 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | Sapitinib | Phase 2 | Active, not recruiting | UNICANCER | 2014-11-24 |
| Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment | Lapatinib | Phase 2 | Recruiting | Centre Leon Berard | 2014-01-07 |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | Lapatinib | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | 2013-09-20 |
| Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | Lapatinib | Phase 2 | Active, not recruiting | City of Hope Medical Center | 2011-01-10 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Trastuzumab duocarmazine | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 2010-01-05 |